Population pharmacokinetics of gemcitabine and dFdU in pancreatic cancer patients using an optimal design, sparse sampling approach.
Fiche publication
Date publication
mars 2017
Journal
Therapeutic drug monitoring
Auteurs
Membres identifiés du Cancéropôle Est :
Dr FEIN Francine
Tous les auteurs :
Serdjebi C, Gattacceca F, Seitz JF, Fein F, Gagnière J, François E, Abakar-Mahamat A, Deplanque G, Rachid M, Lacarelle B, Ciccolini J, Dahan L
Lien Pubmed
Résumé
Gemcitabine remains a pillar in pancreatic cancer treatment. However, toxicities are frequently observed. Dose adjustment based on therapeutic drug monitoring might help decrease the occurrence of toxicities. In this context, this work aims at describing the pharmacokinetics (PK) of gemcitabine and its metabolite dFdU in pancreatic cancer patients and at identifying the main sources of their PK variability using a population pharmacokinetics approach, despite a sparse sampled-population and heterogeneous administration and sampling protocols.
Mots clés
Antimetabolites, Antineoplastic, pharmacokinetics, Cytidine Deaminase, metabolism, Deoxycytidine, analogs & derivatives, Drug Monitoring, methods, Humans, Pancreatic Neoplasms, drug therapy
Référence
Ther Drug Monit. 2017 Mar;: